Belay Summit™ 2.0 Comprehensive Genomic Profile
Tumor-derived nucleic acid in CSF
- Next-generation sequencing
- 520 genes (SNVs, MNVs, Indels)
- 62 CNVs
- 28 Fusions
- TMB and MSI
For chromosome arm-level loss/gain analysis, see our companion test, Belay Ascent™.
Why choose Belay Summit™ 2.0 Genomic Profile in CSF?
- Molecular characterization can markedly enhance diagnostic accuracy, tumor classification, predictive prognosis, and treatment selection1
- CNS metastasis can have different molecular profiles than primary tumors with distinct targetable mutations, due to clonal evolution during neoplasm migration2
- Genomic abnormalities associated with CNS cancers can be detected prior to performing resections or biopsies that impose clinical risk
1. Park SH, Won J, Kim SI, Lee Y, Park CK, Kim SK, Choi SH. Molecular Testing of Brain Tumor. J Pathol Transl Med. 2017 May;51(3):205-223. doi: 10.4132/jptm.2017.03.08. Epub
2017 May 12. PMID: 28535583; PMCID: PMC5445205.
2. Shen E, Van Swearingen AED, Price MJ, Bulsara K, Verhaak RGW, Baëta C, Painter BD, Reitman ZJ, Salama AKS, Clarke JM, Anders CK, Fecci PE, Goodwin CR, Walsh KM. A Need for More Molecular Profiling in Brain Metastases. Front Oncol. 2022 Jan 25;11:785064. doi: 10.3389/fonc.2021.785064. PMID: 35145903; PMCID: PMC8821807.
3. Khurana S, Keo V, Larson A, Udhane V, Adams JN, Acevedo A, Peltier T, Sanchez D, Domagala BA, Vo SA, Mitchell K, Ellis D, Muhammedov B, Al-Saffar SI, Hernandez KM, Bettegowda C, Douville C, Schilter KF, Nie Q, Reddi HV*. Analytical Validation and Clinical Sensitivity of the Belay Summit™ 2.0 Cerebrospinal Fluid Liquid Biopsy Test—An Expanded Comprehensive Genomic Profiling Platform for Central Nervous System Malignancies.2026. Cancers. 18(2):256.
